Display options
Cite
Sanaei M, Ebrahimi M, Banazadeh Z, et al. Consequences of AphanizomenonFlos-aquae(AFA) extract (Stemtech (TM) ) on metabolic profile of patients with type 2 diabetes. J Diabetes Metab Disord. 2015;14:50doi: 10.1186/s40200-015-0177-7.
Sanaei, M., Ebrahimi, M., Banazadeh, Z., Shafiee, G., Khatami, F., Ahadi, Z., & Heshmat, R. (2015). Consequences of AphanizomenonFlos-aquae(AFA) extract (Stemtech (TM) ) on metabolic profile of patients with type 2 diabetes. Journal of diabetes and metabolic disorders, 1450. https://doi.org/10.1186/s40200-015-0177-7
Sanaei, Maryam, et al. "Consequences of AphanizomenonFlos-aquae(AFA) extract (Stemtech (TM) ) on metabolic profile of patients with type 2 diabetes." Journal of diabetes and metabolic disorders vol. 14 (2015): 50. doi: https://doi.org/10.1186/s40200-015-0177-7
Sanaei M, Ebrahimi M, Banazadeh Z, Shafiee G, Khatami F, Ahadi Z, Heshmat R. Consequences of AphanizomenonFlos-aquae(AFA) extract (Stemtech (TM) ) on metabolic profile of patients with type 2 diabetes. J Diabetes Metab Disord. 2015 Jun 24;14:50. doi: 10.1186/s40200-015-0177-7. eCollection 2015. PMID: 26131436; PMCID: PMC4485343.
Copy Download .nbib Format: NLM
Share it on

J Diabetes Metab Disord. 2015 Jun 24;14:50. doi: 10.1186/s40200-015-0177-7. eCollection 2015.

Consequences of AphanizomenonFlos-aquae(AFA) extract (Stemtech (TM) ) on metabolic profile of patients with type 2 diabetes.

Journal of diabetes and metabolic disorders

Maryam Sanaei, Mehdi Ebrahimi, Zahra Banazadeh, Gita Shafiee, Fatemeh Khatami, Zeinab Ahadi, Ramin Heshmat

Affiliations

  1. Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  2. Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran ; Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  3. Lolagar hospital, Iran University of Medical Sciences, Tehran, Iran.

PMID: 26131436 PMCID: PMC4485343 DOI: 10.1186/s40200-015-0177-7

Abstract

BACKGROUND: Blue- green algae is one of the most nutrient dense foods which is rich in substances that have useful effects on human health. The purpose of this study was to evaluate the effectiveness of a water- soluble extract of the cyanophyta Aphanizomenon Flos-aquae (Stemtech (TM) ) as a functional supplement on CD markers, lipid profile, glucose levels as well as its side effects in Iranian patients with type 2 diabetes.

METHODS: During this randomized, double-blind, placebo-controlled trial 49 type 2 diabetic patients, aged between 20 and 60 years with a HbA1C ≥ 7.5 %, were allocated. Patients were divided into two groups of placebo and treated with an equal ratio 1:1. The subjects in StemtechTM group received one capsule of StemFlo (508 mg) before breakfast and two capsules of StemEnhance (500 mg) after each meal for a period of 12 weeks, and placebo group was instructed to take placebo with the same pattern. During the intervention period, subjects were asked to keep usual diet and prohibited to take any functional foods or dietary supplements. Metabolic panel has been measured as the primary outcome of study at the beginning and end of the intervention period via blood sampling.

RESULTS: Stemtech (TM) supplementation for 12 weeks decreased fasting blood glucose (FBG) and Glycatedhemoglobin (HbA1c). Mean serum chemistry parameters (Triglyceride, Total Cholesterol, LDL, HDL, CRP, AST, ALT, BUN and Creatinine) as well as CD 34(+), IL-6, TNF-α in treated and control groups before and after the study showed no considerable dissimilarities.

CONCLUSION: StemtechTM intervention brought in positive consequence on blood glucose levels in Iranian patients with type 2 diabetes, consequently suggests the Stemtech (TM) as a functional food for the management of diabetes.

Keywords: Aphanizomenonflos-aquae(AFA); CD34; StemtechTM; Type 2 Diabetes

References

  1. J Med Food. 2001 Winter;4(4):193-199 - PubMed
  2. J Cell Biochem. 2005 Dec 15;96(6):1149-56 - PubMed
  3. Immunopharmacol Immunotoxicol. 1996 Aug;18(3):457-63 - PubMed
  4. Diabetes Res Clin Pract. 2010 Mar;87(3):293-301 - PubMed
  5. Transplant Proc. 2006 Apr;38(3):967-9 - PubMed
  6. Cardiovasc Revasc Med. 2007 Jul-Sep;8(3):189-202 - PubMed
  7. Arch Toxicol Suppl. 1982;5:271-6 - PubMed
  8. Nutr Cancer. 1995;24(2):197-202 - PubMed
  9. J Nutr Sci Vitaminol (Tokyo). 1998 Dec;44(6):841-51 - PubMed
  10. Am J Physiol Heart Circ Physiol. 2005 Jun;288(6):H2557-67 - PubMed
  11. J Med Food. 2002 Summer;5(2):91-6 - PubMed
  12. Clin Exp Metastasis. 1998 Aug;16(6):541-50 - PubMed
  13. Diabetes Care. 2004 May;27(5):1047-53 - PubMed
  14. J Med Food. 2013 Feb;16(2):103-11 - PubMed
  15. N Engl J Med. 1976 Aug 19;295(8):443-4 - PubMed
  16. Biochem Pharmacol. 1998 Apr 1;55(7):1071-6 - PubMed
  17. Stem Cells. 2007 Jul;25(7):1737-45 - PubMed
  18. Biol Chem. 2007 May;388(5):547-54 - PubMed
  19. Curr Med Chem. 2003 Aug;10(15):1317-27 - PubMed
  20. Int J Stem Cells. 2013 May;6(1):1-11 - PubMed
  21. Handb Exp Pharmacol. 2006;(174):185-227 - PubMed
  22. Immunopharmacol Immunotoxicol. 1996 Aug;18(3):465-76 - PubMed
  23. Life Sci. 2002 Apr 19;70(22):2665-73 - PubMed
  24. Ecotoxicol Environ Saf. 1999 Sep;44(1):73-80 - PubMed
  25. Folia Microbiol (Praha). 1994;39(4):301-3 - PubMed
  26. Diabetes Res Clin Pract. 2011 Dec;94(3):311-21 - PubMed
  27. Stroke. 2001 Apr;32(4):1005-11 - PubMed
  28. Pediatrics. 2000 Mar;105(3 Pt 1):671-80 - PubMed

Publication Types